Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Sarcoma 1Gynecologic 1Genitourinary 1CNS 1Breast 1

Conditions

Wilms Tumor 1Uterine Cervical Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Neoplasms 1Lung Neoplasms 1Kidney Neoplasms 1Brain Neoplasms 1

Interventions

pembrolizumab 28Docetaxel 21Gemcitabine 19Nivolumab 15Paclitaxel 13Prednisone 12Leuprolide 11pazopanib 10Radiotherapy 10Cisplatin 10Sunitinib 9Sorafenib 9Ipilimumab 8Blood Specimen Collection 8Bevacizumab 8avelumab 7atezolizumab 7Therapeutics 7Thalidomide 7Cyclophosphamide 7Carboplatin 7Standard of Care 6Radiation 6Mitomycin 6Interleukin-2 6Cetuximab 6Axitinib 6padeliporfin 5enzalutamide 5cemiplimab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × tariquidar × Genitourinary × Clear all
NCT00011414 2019-07-16

Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
29 enrolled
CNSGenitourinarySarcoma

Brain Neoplasms, Neoplasms, Wilms Tumor, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡